NCT00199875View on ClinicalTrials.gov

Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 6, 2005

Primary Completion Date

March 14, 2013

Study Completion Date

March 14, 2013

Conditions
Renal Cell CarcinomaKidney NeoplasmRenal CancerKidney Cancer
Interventions
DRUG

Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)

Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Ludwig Institute for Cancer Research

OTHER